Camozzi V, Frigo A C, Zaninotto M, Sanguin F, Plebani M, Boscaro M, Schiavon L, Luisetto G
Department of Medicine, Division of Endocrinology, University of Padova, Via Ospedale 105, 35128, Padova, Italy.
Department of Cardiac, Thoracic and Vascular Sciences, Biostatistics, Epidemiology and Public Health Unit, University of Padova, via Loredan 18, 35131, Padova, Italy.
Osteoporos Int. 2016 Aug;27(8):2593-602. doi: 10.1007/s00198-016-3574-y. Epub 2016 Mar 30.
After a single cholecalciferol load, peak serum 25-hydroxycholecalciferol (25OHD) is lower in individuals with a higher body mass index (BMI), probably due to it being distributed in a greater volume. Its subsequent disappearance from the serum is slower the higher the individual's BMI, probably due to the combination of a larger body volume and a slower release into the circulation of vitamin D stored in adipose tissue.
The aim of the study is to examine 25-hydroxycholecalciferol (25OHD) response to a single oral load of cholecalciferol in the normal weight, overweight, and obese.
We considered 55 healthy women aged from 25 to 67 years (mean ± SD, 50.8 ± 9.5) with a BMI ranging from 18.7 to 42 kg/m(2) (mean ± SD, 27.1 ± 6.0). The sample was divided into three groups by BMI: 20 were normal weight (BMI ≤ 25 kg/m(2)), 21 overweight (25.1 ≤ BMI ≤ 29.9 kg/ m(2)), and 14 obese (BMI ≥ 30 kg/m(2)). Each subject was given 300,000 IU of cholecalciferol orally during lunch. A fasting blood test was obtained before cholecalciferol loading and then 7, 30, and 90 days afterwards to measure serum 25OHD, 1,25 dihydroxyvitamin D [1,25 (OH)2D], parathyroid hormone (PTH), calcium (Ca), and phosphorus (P). Participants' absolute fat mass was measured using dual energy X-ray absorptiometry (DEXA).
The fat mass of the normal weight subjects was significantly lower than that of the overweight, which in turn was lower than that of the obese participants. Serum 25OHD levels increased significantly in all groups, peaking 1 week after the cholecalciferol load. Peak serum 25OHD levels were lower the higher the individuals' BMI. After peaking, the 25OHD levels gradually decreased, following a significantly different trend in the three groups. The slope was similar for the overweight and obese, declining significantly more slowly than in the normal weight group. In the sample as a whole, there was a weakly significant negative correlation between fat mass and baseline 25OHD level, while this correlation became strongly significant at all time points after cholecalciferol loading.
The lower peak 25OHD levels seen in the obese and overweight is probably due to the cholecalciferol load being distributed in a larger body volume. The longer persistence of 25OHD in their serum could be due to both their larger body volume and a slower release into the circulation of the vitamin D stored in their adipose tissue.
单次服用胆钙化醇后,体重指数(BMI)较高的个体血清25-羟胆钙化醇(25OHD)峰值较低,这可能是因为它分布在更大的体积中。个体的BMI越高,其血清中25OHD随后的消失速度越慢,这可能是由于更大的身体体积以及储存在脂肪组织中的维生素D释放到循环系统中的速度较慢共同导致的。
本研究的目的是检测正常体重、超重和肥胖个体对单次口服胆钙化醇后25-羟胆钙化醇(25OHD)的反应。
我们纳入了55名年龄在25至67岁(平均±标准差,50.8±9.5)的健康女性,其BMI范围为18.7至42kg/m²(平均±标准差,27.1±6.0)。样本根据BMI分为三组:20名正常体重(BMI≤25kg/m²),21名超重(25.1≤BMI≤29.9kg/m²),14名肥胖(BMI≥30kg/m²)。每位受试者在午餐时口服300,000IU胆钙化醇。在服用胆钙化醇前进行空腹血液检测,然后在服用后7天、30天和90天检测血清25OHD、1,25-二羟维生素D[1,25(OH)2D]、甲状旁腺激素(PTH)、钙(Ca)和磷(P)。使用双能X线吸收法(DEXA)测量参与者的绝对脂肪量。
正常体重受试者的脂肪量显著低于超重受试者,而超重受试者的脂肪量又低于肥胖参与者。所有组的血清25OHD水平均显著升高,在服用胆钙化醇后1周达到峰值。个体的BMI越高,血清25OHD峰值水平越低。达到峰值后,25OHD水平逐渐下降,三组呈现出显著不同的趋势。超重和肥胖组的下降斜率相似,下降速度明显慢于正常体重组。在整个样本中,脂肪量与基线25OHD水平之间存在微弱的负相关,而在服用胆钙化醇后的所有时间点,这种相关性变得非常显著。
肥胖和超重个体中较低的25OHD峰值水平可能是由于胆钙化醇剂量分布在更大的身体体积中。其血清中25OHD持续时间较长可能是由于他们更大的身体体积以及储存在脂肪组织中的维生素D释放到循环系统中的速度较慢。